R-CHOP is a chemotherapy regimen commonly used in the treatment of non-Hodgkin lymphoma (NHL), specifically the most common type called diffuse large B-cell lymphoma (DLBCL).
R-CHOP stands for:
R – Rituximab: A monoclonal antibody that targets a protein called CD20 found on the surface of B-cells, which helps to destroy cancerous B-cells.
C – Cyclophosphamide: A chemotherapy drug that works by interfering with the growth and division of cancer cells. H – Doxorubicin (hydroxydaunorubicin): A chemotherapy drug that inhibits the growth of cancer cells by interfering with their DNA replication.
O – Vincristine (Oncovin): A chemotherapy drug that disrupts the formation of microtubules, essential for cell division, thus preventing cancer cells from multiplying.
P – Prednisone: A corticosteroid that helps to reduce inflammation and suppress the immune system.
The R-CHOP protocol is typically administered in cycles, with each cycle lasting around three weeks. It is often given for a total of six to eight cycles, depending on the specific characteristics of the lymphoma and the individual patient’s response to treatment.
It’s important to note that the R-CHOP protocol may be modified or personalized based on the patient’s overall health, age, and specific characteristics of the lymphoma. Treatment decisions should always be made in consultation with a medical oncologist or hematologist who specializes in lymphoma.
